Package Leaflet: Information for the Patient
Circadin 2 mg Prolonged-Release Tablets
Melatonin
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the Package Leaflet:
The active substance of Circadin is melatonin and it belongs to a group of natural hormones produced by the body.
Circadin is used on its own for the short-term treatment of primary insomnia (persistent difficulty in falling asleep or staying asleep or poor quality sleep) in patients over 55 years of age. "Primary" means that the insomnia does not have any known cause, whether medical, mental or environmental.
Do not take Circadin
Warnings and precautions
Consult your doctor or pharmacist before taking Circadin.
Children and adolescents
This medicine should not be given to children or adolescents from 0 to 18 years, as it has not been evaluated in this population and its effects are not known. For administration to children from 2 to 18 years, another melatonin medicine may be more suitable; consult your doctor or pharmacist.
Taking Circadin with other medicines
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. These medicines include:
Taking Circadin with food, drinks and alcohol
Take Circadin after you have eaten some food. Do not drink alcohol before, after or while taking Circadin, as it reduces the effectiveness of Circadin.
Pregnancy and breastfeeding
Do not take Circadin if you are pregnant, think you may be pregnant or are planning to have a baby. Consult your doctor or pharmacist before using this medicine.
Driving and using machines
Circadin may cause drowsiness. In this case, do not drive or operate machinery. Consult your doctor if you experience persistent drowsiness.
Circadin contains lactose monohydrate
Circadin contains lactose monohydrate. If your doctor has told you that you have an intolerance to some sugars, consult with them before taking this medicine.
Follow exactly the administration instructions of this medicine given by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
The recommended dose is one tablet (2 mg) of Circadin per day, taken orally after eating some food, 1 or 2 hours before bedtime. This dose may be continued for up to thirteen weeks.
You should swallow the tablet whole. Circadin tablets should not be crushed or broken in half.
If you take more Circadin than you should
If you accidentally take more medicine than you should, go to your doctor or pharmacist as soon as possible.
Taking a higher dose than recommended per day may cause drowsiness.
If you forget to take Circadin
If you forget to take the tablet, take it as soon as you remember, before going to bed, or wait until the next dose and then continue as before.
Do not take a double dose to make up for forgotten doses.
If you stop taking Circadin
Stopping or ending treatment prematurely does not cause any known adverse effects. The use of Circadin does not cause withdrawal effects after treatment is finished.
If you have any other questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
If you experience any of the following serious side effects, stop taking the medicine and contact your doctor immediately:
Uncommon:(may affect up to 1 in 100 people)
Rare:(may affect up to 1 in 1,000 people)
If you experience any of the following non-serious side effects, contact your doctor or pharmacist:
Uncommon:(may affect up to 1 in 100 people)
Irritability, nervousness, restlessness, insomnia, abnormal dreams, nightmares, anxiety, migraine, headache, lethargy (fatigue, lack of energy), restlessness associated with increased activity, dizziness, exhaustion, high blood pressure, abdominal pain, indigestion, mouth ulcers, dry mouth, nausea, alteration of blood composition that may cause a yellowish tint to the skin or eyes, skin inflammation, night sweats, itching, skin rash, dry skin, pain in the limbs, menopausal symptoms, feeling of weakness, glucose in the urine, excess protein in the urine, abnormal liver function and weight gain.
Rare:(may affect up to 1 in 1,000 people)
Herpes zoster, increased concentration of fat molecules in the blood, reduced calcium concentration in the blood, reduced sodium concentration in the blood, mood alteration, aggression, agitation, crying, stress symptoms, waking up early, increased libido (increased sexual desire), depressive mood, memory impairment, attention alteration, daydreaming, restless legs syndrome, poor quality sleep, sensation of pins and needles, increased tear production, dizziness when standing up or sitting down, hot flashes, acid reflux, digestive disorders, mouth ulcers, tongue ulcers, stomach discomfort, vomiting, abnormal intestinal sounds, gas, excessive saliva production, bad breath, abdominal discomfort, stomach disorders, stomach mucosa inflammation, eczema, skin redness, hand dermatitis, skin redness and itching, nail disorders, arthritis, muscle spasms, neck pain, nocturnal cramps, prolonged erection that may be painful, prostate inflammation, fatigue, pain, thirst, increased urine volume, need to urinate at night, increased liver enzymes, blood electrolyte abnormalities and laboratory test abnormalities.
Frequency not known:(cannot be estimated from the available data)
Hypersensitivity reaction, swelling of the mouth or tongue, skin swelling and abnormal milk secretion.
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Annex V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of the month shown.
Do not store above 25°C. Store in the original package to protect from light.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition of Circadin
The active substance is melatonin. Each prolonged-release tablet contains 2 mg of melatonin.
The other ingredients (excipients) are ammonio methacrylate copolymer type B, calcium hydrogen phosphate dihydrate, lactose monohydrate, colloidal anhydrous silica, talc and magnesium stearate.
Appearance of the product and pack contents
Circadin 2 mg prolonged-release tablets are presented as biconvex, round, white or almost white tablets. Each carton of tablets contains a blister strip with 7, 20 or 21 tablets or a cardboard box with two blister strips with 15 tablets each (30 tablets in total). Not all pack sizes may be marketed.
Marketing authorisation holder and manufacturer
Marketing authorisation holder:
RAD Neurim Pharmaceuticals EEC SARL
4 rue de Marivaux
75002 Paris
France
Email: regulatory@neurim.com
Manufacturer:
Responsible centres for batch release in the EEA:
Temmler Pharma GmbH & Co. KG
Temmlerstrasse 2
35039 Marburg
Germany
Iberfar - Indústria Farmacêutica S.A.
Rua Consiglieri Pedroso, n.o 121-123 - Queluz de Baixo
Barcarena, 2734-501
Portugal
Rovi Pharma Industrial Services, S.A.
Vía Complutense, 140
Alcalá de Henares
Madrid, 28805
Spain
You can obtain further information on this medicine by contacting the local representative of the marketing authorisation holder.
Belgium/Belgique/Belgien Takeda Belgium Tel: +32 2 464 06 11 medinfoEMEA@takeda.com | Lithuania RAD Neurim Pharmaceuticals EEC SARL Tel: +33 185149776 (FR) e-mail: neurim@neurim.com |
RAD Neurim Pharmaceuticals EEC SARL Τel: +33 185149776 (FR) e-mail: neurim@neurim.com | Luxembourg/Luxemburg Takeda Belgium Tél/Tel: +32 2 464 06 11 (BE) medinfoEMEA@takeda.com |
Czech Republic RAD Neurim Pharmaceuticals EEC SARL Tel: +44 7563543352 (UK) e-mail: neurim@neurim.com | Hungary RAD Neurim Pharmaceuticals EEC SARL Tel: +33 185149776 (FR) e-mail: neurim@neurim.com |
Denmark Takeda Pharma A/S Tlf: +45 46 77 11 11 | Malta RAD Neurim Pharmaceuticals EEC SARL Tel: +33 185149776 (FR) e-mail: neurim@neurim.com |
Germany MEDICE Arzneimittel Pütter GmbH & Co. KG Tel: +49 (0)2371 9370 info@medice.de | Netherlands Takeda Nederland b.v Tel: +31 20 203 5492 medinfoEMEA@takeda.com |
Estonia RAD Neurim Pharmaceuticals EEC SARL Tel: +33 185149776 (FR) e-mail: neurim@neurim.com | Norway Takeda AS Tlf: +47 800 800 30 medinfoEMEA@takeda.com |
Greece TAKEDA ΕΛΛΑΣ Α.Ε. Τηλ: +30 210 6387800 medinfoEMEA@takeda.com | Austria SANOVA PHARMA GesmbH Tel.: +43 (01) 80104-0 e-mail: sanova.pharma@sanova.at |
Spain EXELTIS HEALTHCARE, S.L. Tfno: +34 91 7711500 | Poland MEDICE Arzneimittel Pütter GmbH & Co. KG Tel.: + 48-(0)22 642 2673 e-mail: office@medice.pl |
France BIOCODEX Tél: +33 (0)1 41 24 30 00 e-mail: medinfo@biocodex.com | Portugal Italfarmaco, Produtos Farmacêuticos, Lda. Tel. +351 214 342 530 e-mail: geral@itf-farma.pt |
Croatia RAD Neurim Pharmaceuticals EEC SARL Tel: +33 185149776 (FR) e-mail: neurim@neurim.com | Romania RAD Neurim Pharmaceuticals EEC SARL Tel: +33 185149776 (FR) e-mail: neurim@neurim.com |
Ireland RAD Neurim Pharmaceuticals EEC SARL Tel: +33 185149776 (FR) e-mail: neurim@neurim.com | Slovenia RAD Neurim Pharmaceuticals EEC SARL Tel: +33 185149776 (FR) e-mail: neurim@neurim.com |
Iceland Vistor hf. Simi: +354 535 7000 | Slovakia RAD Neurim Pharmaceuticals EEC SARL Tel: +33 185149776 (FR) e-mail: neurim@neurim.com |
Italy Fidia Farmaceutici S.p.A. Tel: +39 049 8232222 e-mail: info@fidiapharma.it | Finland Takeda Oy Puh/Tel: +358 20 746 5000 |
Cyprus RAD Neurim Pharmaceuticals EEC SARL Τηλ : +33 185149776 (FR) e-mail: neurim@neurim.com | Sweden Takeda Pharma AB Tel: +46 8 731 28 00 medinfoEMEA@takeda.com |
Latvia RAD Neurim Pharmaceuticals EEC SARL Tel: +33 185149776 (FR) e-mail: neurim@neurim.com | United Kingdom (Northern Ireland) RAD Neurim Pharmaceuticals EEC SARL Tel: +33 185149776 (FR) e-mail: neurim@neurim.com |
Date of last revision of this leaflet:{month YYYY}
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu